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ORIGINAL ARTICLE
Does the constellation of risk factors with and without
abdominal adiposity associate with different
cardiovascular mortality risk?
The DECODE Study Group
Aims: To evaluate whether the metabolic syndrome (MetS) defined by the International Diabetes Federation (IDF) criteria,
which has abdominal adiposity as a mandatory element, predicts cardiovascular disease (CVD) mortality better than the cluster
of other IDF-defined abnormalities not including abdominal adiposity.
Methods: Data from nine European population-based studies, including 7782 men and 7739 women (aged 30–89 years), with
a median follow-up of 8.55 years, were jointly analyzed. Hazard ratios for CVD mortality were calculated with Cox regression
models.
Results: In total, 41% of the men and 38% of the women had the IDF MetS. Individuals with the IDF MetS were by definition
more obese and had a higher prevalence of diabetes than non-obese subjects with X2 IDF abnormalities; whereas non-obese
men with X3 factors had more atherogenic lipid profiles. Multivariate adjusted hazard ratio for CVD death in men and women
with the IDF MetS was 2.44 (1.69–2.98) and 2.32 (1.27–4.23); in non-obese men with 2 and X3 factors the hazard ratio
was 1.60 (1.12–2.30) and 2.44 (1.62–3.66), respectively, and in non-obese women with 2 factors the hazard ratio was 2.41
(1.09–5.33).
Conclusions: The cluster of the CVD risk factors predicted CVD mortality regardless of the presence or absence of the abdominal
adiposity. Inclusion of abdominal adiposity as a prerequisite will miss those non-obese individuals who have increased CVD
mortality.
International Journal of Obesity (2008) 32, 757–762; doi:10.1038/sj.ijo.0803797; published online 22 January 2008
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Introduction
The International Diabetes Federation (IDF) proposed a new
criteria for the metabolic syndrome (MetS) during the First
International Congress on Prediabetes and Metabolic
Syndrome on 14 April 2005.1 These new IDF diagnostic
criteria emphasized the importance of abdominal adiposity,
as measured by waist circumference, considering it as a
prerequisite for the definition; an ethnically specific waist
cutoff value for abdominal adiposity and a low fasting
plasma glucose cutoff value for impaired fasting glucose were
recommended.
The IDF recommendation reflects the fact that obesity is
the common component of the MetS and together with
insulin resistance might be one of the underlying causes of
the MetS.1 It is, however, still unknown whether the cluster
of cardiovascular disease (CVD) risk factors included in the
definition of the MetS with abdominal adiposity has a
different CVD mortality from that without obesity. This
question was studied using the data from nine European
Studies participating in the Diabetes Epidemiology: Collabora-
tive Analysis of Diagnostic Criteria in Europe (DECODE) study.
Study populations and methods
The recruitment of the DECODE study has been described in
detail previously.2–8 Briefly, researchers who had performed
European epidemiological studies on diabetes and abnorm-
alities of glucose homeostasis, using a standard 2-h 75 g oral
glucose tolerance test, were invited to participate. Individual
data on fasting and 2-h glucose concentrations and a
number of other variables were sent to the Diabetes and
Genetic Epidemiology Unit of the National Public Health
Institute in Helsinki, Finland, for the collaborative data
analyses. All the studies involved in DECODE study were
approved by the local ethical committee and informed
consent was collected by the each centers. Agreement for
the collaborating data analyses was collected from each
center with the signature of the principal investigator.
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All the studies included in the current data analysis
(Appendix 1 Table A1) are population-based. Except Uppsala
study which only recruited men, all the studies comprised
men and women. The CVD mortality was uniformly
classified according to the International Classification of
Disease 9 or 10. The glucose oxidase method for blood
glucose and enzymatic method for lipid were applied in all
study laboratories (Appendix 1 Table A1). Waist circumfer-
ence was measured at the midway between the lower rib
margin and iliac crest in all except the Cremona study, where
it was measured at the level of umbilicus. Although the
questionnaire to record the smoking status varied among
centers, smoking status can be classified into non-smoker,
current smoker or ex-smoker according to self-reported
information.
Classification of subjects
Because the data on lipid-lowering medication was not
available, a modified rather than the original IDF definition
for the MetS was applied in the current study. Individuals
were considered as having the IDF MetS if they had
abdominal adiposity (waist girth X94 cm in men or
X80 cm in women for Europid) plus any two of the
following four abnormalities:
(1) Raised triglycerides: serum triglycerides X1.7 mM;
(2) reduced high-density lipoprotein cholesterol (HDL-c):
HDL-c o1.03 mM in men and o1.29 mM in women;
(3) raised blood pressure: systolic blood pressure X130mmHg
and/or diastolic blood pressure X85 mm Hg, or drug
treatment of previously diagnosed hypertension and
(4) raised fasting plasma glucose: fasting plasma glucose
X5.6 mM, or previously diagnosed type 2 diabetes.
Diabetes was defined as individuals with a prior history of
diabetes or with fasting plasma glucose X7.0 mM and/or 2-h
post-challenge glucose X11.1 mM.9
Statistical analysis
Because of the skewed distribution, plasma glucose, tri-
glyceride and HDL-c were logarithmically transformed to get
a near normal distribution and the geometric means were
presented. The difference between groups was tested with
analysis of variance and means were calculated with
general linear model adjusting for age and study. The Cox
proportional hazard model adjusted for age, study, serum
cholesterol and smoking was performed to estimate hazard
ratios for CVD death associated with the different clusters of
metabolic abnormalities. All data analyses were performed
with the SPSS for Windows 15.0 software package.
Results
A total of 15 521 subjects (7782 men and 7739 women) from
nine studies participating in the DECODE study formed the
present study population (Table 1). The mean age of study
participants ranged from 47 to 71 years. The baseline
examination was carried out around the beginning of
1990s, except for FINRISK 2002. The maximum length of
follow-up ranged from 3.9 to 20.6 years. A total of 564
participants (436 men) died of CVD during the follow-up.
The IDF criteria defined 53.9% men and 62.9% women of
the study population as having abdominal adiposity, and the
prevalence of the IDF MetS was 41.2% in men and 37.9% in
women (Table 2). In all, 20.3% men and 9.5% women had
two or more abnormalities but without abdominal adiposity.
Non-obese individuals with 3–4 (out of four) IDF MetS risk
factors were rare.
Non-obese individuals with two IDF metabolic abnormal-
ities had worse cardiovascular risk profiles than the non-
obese subjects with one abnormality or less, but more
favorable than those with the IDF MetS (Tables 2 and 3).
Subjects with the IDF MetS were, by definition, more obese
and also had higher blood pressure than the non-obese









Response rate (%) Follow-up
(maximum), years
No. of CVD death (%)
Baseline Follow-up Men Women
Cremona, Italy 2042 59 (40–88) 44.0 1990–1991 58 100.0 6.9 30 (3.3) 24 (2.1)
MONICA, Finland, 1992 1855 54 (44–64) 45.3 1992 77 100.0 12.0 50 (5.9) 15 (1.5)
Hoorn, The Netherlands 2436 62 (49–77) 45.8 1989–1991 71 97.3 10.2 73 (6.5) 42 (3.2)
Newcastle, UK 749 55 (30–76) 51.1 1993–1994 96 100.0 10.6 25 (6.5) 8 (2.2)
MONICA, Poland 351 58 (44–73) 47.0 1992–1993 71 98.6 6.6 13 (7.9) 2 (1.1)
MONICA, Sweden, 1986 438 47 (30–64) 51.1 1986 82 100.0 20.6 25 (11.2) 8 (3.7)
MONICA, Sweden, 1992 697 47 (30–64) 47.5 1992 81 100.0 16.6 9 (2.7) 6 (1.6)
MONICA, Sweden, 1994 910 53 (30–74) 48.7 1994 77 100.0 12.6 19 (4.3) 11 (2.4)
Ely, UK 1026 54 (40–69) 41.4 1990–1992 74 99.2 15.7 21 (4.9) 6 (1.0)
Uppsala, Sweden 1161 71 (69–74) 100.0 1991–1995 65 100.0 12.4 142 (12.2) F
FINRISK 2002, Finland 3856 58 (30–74) 46.6 2002 67 100.0 3.9 29 (1.6) 6 (0.3)
Total 15 521 58 (30–89) 41.4 F F F 20.6 436 (5.6) 128 (1.7)
Abbreviation: CVD, cardiovascular disease.
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individuals with 3–4 abnormalities; but the lipid
profiles were more atherogenic in the latter than in the
former.
In non-obese men, the multivariate adjusted hazard ratio
increased significantly with increasing number of factors
clustered from 2 to 3–4 as compared with non-obese men
with p1 factor (reference group). This was also observed for
non-obese women with two factors (Table 4). Compared
with people with the IDF MetS, the hazard ratio was lower for
non-obese men with two factors (0.45, 95% CI 0.34–0.59),
but was not significantly different for non-obese men with
3–4 factors (1.09, 95% CI 0.77–1.54) and for non-obese
women with two factors (1.04, 95% CI 0.58–1.92).
Discussion
Both the abdominal adiposity and IDF MetS were
common in this study population, and the IDF MetS
identified people with increased CVD mortality. Non-obese
people with two or more IDF MetS factors were less
prevalent, but they had higher CVD mortality compared
with that in non-obese individuals with less IDF MetS
Table 2 Baseline characteristics of subjects with different clusters of metabolic abnormalities according to the IDF criteria
Metabolic abnormalities a Non-abdominal adiposity Abdominal adiposity
p1 2 X3 p1 X2 (IDF MetS)
Men
No. (%) of subjects 1949 (25.0) 1082 (13.9) 495 (6.4) 1046 (13.4) 3210 (41.2)
Age (years) 56 (55.8–56.7) 58 (57.8–59.0)*w 58 (57.3–59.1)*w 59 (58.6–59.8)* 60 (59.7–60.4)*
Body mass index (kg m2) 23.7 (23.6–23.8) 24.5 (24.3–24.6)*w 24.9 (24.7–25.2)*w 28.0 (27.8–28.2)* 29.4 (29.4–29.5)*
Waist (cm) 86 (85.5–86.1) 87 (87.1–87.9)*w 89 (88.3–89.5)*w 100 (99.9–100.7)* 104 (103.4–103.9)*
Systolic BP (mm Hg) 132 (130.8–132.4) 143 (141.5–143.7)*w 144 (142.1–145.4)*w 135 (134.1–136.3)* 147 (146.5–147.8)*
Diastolic BP (mm Hg) 78 (77.7–78.6) 83 (82.4–83.7)*w 84 (83.4–85.2)*w 82 (81.3–82.6)* 87 (86.8–87.6)*
Fasting glucose (mM) 5.21 (5.18–5.25) 5.75 (5.69–5.80)*w 6.08 (6.00–6.16)* 5.28 (5.24–5.33) 6.12 (6.08–6.15)*
2-h glucose (mM) 5.23 (5.15–5.32) 5.95 (5.82–6.08)*w 6.41 (6.21–6.62)*w 5.45 (5.33–5.57)* 6.85 (6.76–6.93)*
Cholesterol (mM) 5.73 (5.68–5.78) 5.88 (5.82–5.95)*w 6.16 (6.06–6.26)*w 5.80 (5.73–5.86) 6.01 (5.97–6.04)*
HDL-cholesterol (mM) 1.42 (1.40–1.43) 1.28 (1.27–1.30)*w 1.02 (1.00–1.05)*w 1.34 (1.32–1.36)* 1.11 (1.10–1.11)*
Triglyceride (mM) 1.00 (0.98–1.02) 1.30 (1.27–1.34)*w 2.19 (2.11–2.28)*w 1.13 (1.10–1.16)* 1.86 (1.83–1.89)*
Current smoker (%) 30.5 (28.5–32.6) 33.7 (30.9–36.6)w 34.3 (30.2–38.5)w 25.0 (22.3–27.6)* 26.6 (25.1–28.2)*
Women
No. (%) of subjects 2140 (27.79) 565 (7.3) 167 (2.2) 1935 (25.0) 2932 (37.9)
Age (years) 52 (51.8–52.6) 57 (56.0–57.5)*w 60 (58.1–60.9)* 56 (56.0–56.8)* 60 (59.4–60.0)*
Body mass index (kg m2) 22.9 (22.7–23.0) 23.5 (23.2–23.8)*w 23.5 (22.9–24.0)w 27.8 (27.7–28.0)* 30.0 (29.9–30.1)*
Waist (cm) 73 (72.8–73.5) 74 (73.2–74.5)w 75 (73.5–75.9)w 89 (88.3–89.0)* 94 (93.5–94.1)*
Systolic BP (mm Hg) 129 (128.3–130.0) 143 (141.1–144.2)*w 142 (138.9–144.7)* 134 (133.5–135.2)* 145 (144.7–146.1)*
Diastolic BP (mm Hg) 75 (74.4–75.4) 81 (80.5–82.3)*w 81 (79.1–82.4)*w 79 (78.5–79.5)* 84 (83.2–84.0)*
Fasting glucose (mM) 5.12 (5.08–5.15) 5.63 (5.57–5.70)*w 5.82 (5.70–5.95)* 5.13 (5.10–5.16) 5.91 (5.87–5.94)*
2-h glucose (mM) 5.32 (5.26–5.39) 6.02 (5.87–6.17)*w 6.51 (6.21–6.82)* 5.57 (5.49–5.64)* 6.84 (6.76–6.92)*
Cholesterol (mM) 5.90 (5.85–5.94) 6.02 (5.93–6.12)w 6.43 (6.26–6.62)*w 6.10 (6.05–6.15)* 6.19 (6.15–6.23)*
HDL-cholesterol (mM) 1.71 (1.69–1.73) 1.51 (1.49–1.54)*w 1.23 (1.19–1.27)*w 1.60 (1.58–1.61)* 1.29 (1.28–1.30)*
Triglyceride (mM) 0.93 (0.92–0.95) 1.15 (1.12–1.19)*w 1.81 (1.71–1.92)*w 1.06 (1.05–1.08)* 1.64 (1.62–1.66)*
Current smoker (%) 24.1 (22.3–25.9) 21.1 (17.7–24.4) 26.3 (19.7–33.0) 19.4 (17.6–21.1)* 20.1 (18.6–21.5)*
Abbreviations: BP, blood pressure; HDL, high-density lipoprotein; IDF, International Diabetes Federation; MetS, metabolic syndrome. Values are means (95% CI)
adjusted for age and study except for noted. aMetabolic abnormalities defined by the IDF criteria, which include: (I) blood pressure X130/85 mm Hg or treated
hypertension; (II) triglyceride X1.7 mM; (III) HDL-cholesterol o1.03 mM in men and o1.29 mM in women and (IV) fasting plasma glucose X5.6 mM or previously
diagnosed diabetes. Po0.05, *compared with non-obese subjects with p1 abnormalities, wcompared with subjects with the IDF MetS.
Table 3 Prevalence (%) of metabolic abnormalities in subjects with different
clusters of abnormalities according to the IDF criteria




p1 2 X3 1 X2 (IDF MetS)
Men
Raised blood pressure 47.1 83.3 89.7 56.9 93.2
Reduced HDL-c 4.3 21.1 61.6 4.1 38.8
Raised TG 4.5 28.3 87.1 5.4 58.1
Raised fasting plasma
glucose
15.4 67.4 79.6 15.6 78.0
Women
Raised blood pressure 37.9 87.3 93.4 54.6 90.9
Reduced HDL-c 7.0 28.8 68.9 7.9 52.1
Raised TG 2.2 18.9 74.9 3.2 50.4
Raised fasting plasma
glucose
12.2 65.0 79.0 10.2 69.1
Abbreviations: HDL-c, high-density lipoprotein cholesterol; IDF, International
Diabetes Federation; MetS, metabolic syndrome; TG, triglyceride. aMetabolic
abnormalities defined by the IDF criteria, which include: (I) blood pressure
X130/85 mm Hg or treated hypertension; (II) triglyceride X1.7 mM; (III) HDL-
c o1.03 mM in men and o1.29 mM in women and (IV) fasting plasma glucose
X5.6 mM or previously diagnosed diabetes.
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factors. The IDF definition of the MetS will miss these non-
obese individuals and thus underestimate the CVD risk in
the population.
The definition of the MetS aims at identifying high-risk
individuals for CVD and type 2 diabetes.1 However, evidence
from studies that have assessed the association between the
MetS and CVD risk is not consistent.10 Some of them
indicated that the MetS, defined with National Cholesterol
Education Program (NCEP) or WHO criteria, is associated
with significantly increased CVD risk, and might be a useful
predictor for CVD events.11–14 There are, however, also
reports suggesting that the MetS did not convey a high CVD
risk or had less power in predicting CVD events than the
individual metabolic abnormality.15–20 Our study revealed
that the IDF criteria of the MetS predicted CVD mortality. By
definition, subjects who did not have abdominal adiposity
but had at least two other factors were not identified by the
IDF criteria, while CVD mortality in such men was as high
as in those with the IDF MetS even after adjusting age,
smoking status and total serum cholesterol. In all, CVD
deaths occurred in 22% men and 9% women in these non-
obese individuals. The evidence from the present study
suggests that the criteria without making a mandatory
condition would be more inclusive of individuals with
increased CVD mortality.
In this study population, non-obese men with two or
more metabolic abnormalities had a higher prevalence of
smoking than others. To check to what extent smoking has
contributed to the increased CVD mortality in these men,
stratified data analyses by smoking status were carried out.
The hazard ratios for CVD mortality in non-obese men
with two or more metabolic abnormalities as compared with
non-obese men with zero or one abnormality were 1.83
(1.11–3.01) in smokers and 1.87 (1.09–3.23) in non-smokers.
The corresponding figures in individuals with the IDF MetS
were 2.21 (1.39–3.49) in smokers and 2.42 (1.52–3.84) in
non-smokers, respectively. The results suggested that the
increased CVD mortality could not be fully attributed to
smoking status.
The merit of the collaborative data analysis is that the
studies included in the current data analysis are all popula-
tion-based and represent the general population of indivi-
dual study location. The statistical power is higher than that
of any single study alone, which can answer questions that
may not be addressed in an individual study. The major
problem of the collaborative data analysis is whether the
data collected or the effect size is homogeneous since each
study had been carried out individually using different
protocols. We noticed, however, that laboratory analyses
for glucose and lipids and the measurement of waist
happened to be quite homogenous. And, the CVD mortality
has been uniformly classified according to the International
Classification of Disease. Moreover, a statistic measuring
study-to-study variation showed that the effect size was not
statistically different from zero (P40.10).21 In addition,
adjustment for study was done in all the data analyses using
pooled data.
In conclusion, the cluster of the CVD risk factors predicted
CVD mortality regardless of whether the abdominal adipo-
sity was present or not. Inclusion of abdominal adiposity as a
prerequisite will miss many non-obese individuals who have
increased CVD mortality.
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Table 4 Number of cardiovascular deaths, cumulative mortality and the hazard ratio in relation to different clusters of metabolic abnormalities according to the
2005 IDF definition of the MetS
Metabolic abnormalities a Non-abdominal adiposity Abdominal adiposity
p1 2 X3 p1 X2 (IDF MetS)
Men
Number of death 62 57 38 56 223
Mortality (95% CI) per
1000 person years
3.3 (2.5–4.1) 6.0 (4.5–7.6) 8.6 (5.9–11.3) 5.9 (4.4–7.5) 8.6 (7.5–9.7)
Hazard ratio (95% CI) 1 1.60 (1.12–2.30) 2.44 (1.62–3.66) 1.45 (1.01–2.08) 2.24 (1.69–2.98)
Women
Number of death 13 12 1 21 81
Mortality (95% CI) per
1000 person years
0.6 (0.3–0.9) 2.4 (1.0–3.7) 0.6 (0.6 to 1.8) 1.3 (0.7–1.8) 3.4 (2.7–4.2)
Hazard ratio (95% CI) 1 2.41 (1.09–5.33) NA 1.19 (0.59–2.40) 2.32 (1.27–4.23)
Abbreviations: HDL-c, high-density lipoprotein cholesterol; IDF, International Diabetes Federation; MetS, metabolic syndrome; NA, not available. Hazard ratio
was estimated adjusting for age, study, total cholesterol and smoking. aMetabolic abnormalities defined by IDF criteria, which include: (I) blood pressure
X130/85 mm Hg or treated hypertension; (II) triglyceride X1.7 mM; (III) HDL-c o1.03 mM in men and o1.29 mM in women and (IV) fasting plasma glucose
X5.6 mM, or previously diagnosed diabetes.
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Appendix
Organization
The Diabetes Epidemiology: Collaborative Analysis
of Diagnostic Criteria in Europe (DECODE) Study was
undertaken in 1997 upon the initiative of the European
Diabetes Epidemiology Group.
Studies and investigators in this collaborative study were
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and J Lindström2
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Helsinki, Helsinki; 2Department of Epidemiology and
Health Promotion, National Public Health Institute,
Helsinki and 3South Ostrobothnia Central Hospital,
Seinäjoki
Italy
Cremona Study: MP Garancini, G Calori and G Ruotolo
Clinical Cardiovascular Biology Research Centre,
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The Uppsala Longitudinal Study of Adult Men (ULSAM):
B Zethelius
Department of Public Health/Geriatrics, Uppsala
University Hospital, Uppsala
UK
Isle of Ely Diabetes Project: NJ Wareham
MRC Epidemiology Unit, Strangeways Research Labs,
Cambridge
Newcastle Heart Project: N Unwin, N Ahmad, KGMM Alberti
and L Hayes
Department of Medicine and Epidemiology and Public
Health, University of Newcastle, Newcastle
Secretariat:
Q Qiao1,2, K Borch-Johnsen3 and J Tuomilehto1,2
1Department of Epidemiology and Health
Promotion, National Public Health Institute, Helsinki,
Finland; 2Department of Public Health, University of
Helsinki, Helsinki, Finland and 3Steno Diabetes Center,
Gentofte, Denmark
Data analysis:
WG Gao1,2 and Q Qiao1,2
1Department of Public Health, University of Helsinki,
Helsinki, Finland and 2Diabetes and Genetic Epidemiology
Unit, Department of Epidemiology and Health Promotion,
National Public Health Institute, Helsinki, Finland
Writing Committee:
WG Gao1,2, Q Qiao1,2, J Tuomilehto1,2, B Balkau3, G
Ruotolo4, G Calor4, MP Garancini4, KMMG Alberti5 and CDA
Stehouwer6
1Department of Public Health, University of Helsinki,
Helsinki, Finland; 2Diabetes and Genetic Epidemiology
Unit, Department of Epidemiology and Health Promotion,
National Public Health Institute, Helsinki, Finland; 3INSERM
U258-IFR69, Paris, France; 4Clinical Cardiovascular Biology
Research Centre, San Raffaele Scientific Institute, Milan,
Italy; 5Department of Endocrinology and Metabolic
Medicine, Mint Wing, St Mary’s Hospital, London, UK and
6Department of Medicine, University Hosptial Maastricht,
AZ Maastricht, The Netherlands
Table A1 Information on the blood sample, glucose and lipid assay, and waist measurement in individual studies involved in the current data analysis
Studies Blood sample
for glucose
Glucose assay Blood sample
for lipid
Lipid assay Waist measurement





At the level of umbilicus
MONICA,
Finland, 1992
Plasma Glucose dehydrogenase Serum Liebermann–Burchard reaction
and enzymatic techniques
(Boehringer-Mannheim)
Midway between the lower







Midway between the lower
rib margin and iliac crest




Toch Products Ltd., UK)
Midway between the lower








Midway between the lower








Midway between the lower
rib margin and iliac crest
Ely, UK Plasma Hexokinase assay Plasma Enzymatic techniques (RA
1000; Bayer Diagnostics,
Basingstoke, Hants, UK)
Midway between the lower












Midway between the lowest
rib and the iliac crest
FINRISK 2002,
Finland





Midway between the lower rib
margin and iliac crest
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